Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-05-05 Regulatory Filings
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals PLC
Regulatory Filings Classification · 95% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals PLC" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a Public Opening Position Disclosure/Dealing Disclosure made by a person holding 1% or more interest in relevant securities during a takeover situation. This type of disclosure relates to insider/significant shareholder activity during a takeover bid, which is a specific regulatory event. While it involves director/insider dealings (DIRS) and major shareholding changes (MRQ), the specific context of Rule 8.3 of the Takeover Code points towards a specialized regulatory filing related to M&A activity or significant ownership changes during a bid. Given the options, this is a highly specific regulatory disclosure related to a takeover scenario. Since there is no specific code for 'Takeover Disclosure Form 8.3', and it details dealings and positions during an offer, it is best classified as a specialized regulatory filing. However, looking closely at the definitions, it is a report of a transaction/position by an insider/major shareholder during a specific event. Since it is not a general Director's Dealing (DIRS) but tied to a takeover, and it is a formal regulatory filing, the closest fit among the provided options that captures specific regulatory reporting outside of standard financials is often the general Regulatory Filings (RNS) or, if we interpret the content as insider trading related to a corporate action, DIRS. Since this is a mandatory disclosure under the Takeover Code, it is a specific regulatory filing. Given the options, and recognizing this is a mandatory disclosure related to ownership during a potential M&A event, it fits best under the general regulatory filing category (RNS) as it doesn't perfectly match DIRS (which usually implies routine insider trading reports) or TAR (which is for the M&A announcement itself). However, since it details dealings by a person with interests, DIRS is also a strong candidate. Rule 8.3 disclosures are mandatory during a 'Rule 2.1 statement' period. Given the focus on 'Dealing Disclosure' and 'Interests', DIRS (Director's Dealing) is often used broadly for insider transactions, but this is specifically a Takeover Code filing. I will classify this as RNS (Regulatory Filings) as it is a specific, non-standard regulatory report mandated by the Takeover Panel, which serves as the best general regulatory fallback.
2023-05-05 English
Rule 2.9 Announcement
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly states it is a "Rule 2.9 Announcement" under the "City Code on Takeovers and Mergers (the 'Code')". It provides the total number of shares in issue (113,879,778) as required by Rule 2.9. This type of announcement is directly related to a takeover or merger situation, which falls under the scope of M&A Activity (TAR). Although it is a regulatory announcement distributed via RNS, the specific content (Rule 2.9 disclosure) makes the M&A category (TAR) more precise than the general Regulatory Filings (RNS) or Transaction in Own Shares (POS). Since the document is short and relates to a specific event within a takeover context, TAR is the most appropriate classification.
2023-05-05 English
Form 8.3 - Dechra Pharmaceuticals PLC
M&A Activity Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals PLC' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a Public Opening Position Disclosure/Dealing Disclosure by a person with interests in relevant securities representing 1% or more, typically filed during a takeover situation. This type of disclosure relates to insider/major shareholder dealings during a M&A event. While it involves share transactions, the specific regulatory context (Takeover Code Rule 8.3 disclosure) is most closely aligned with M&A Activity (TAR) or Director's Dealing (DIRS). Since this is a disclosure by an external party (Grandeur Peak Global Advisors, LLC) regarding their position during an offer involving Dechra Pharmaceuticals, it strongly indicates activity related to a takeover or merger proposal. Therefore, TAR (M&A Activity) is the most appropriate classification over DIRS, which usually covers director transactions.
2023-05-05 English
Form 8.3 - Dechra Pharmaceuticals plc
Director's Dealing Classification · 90% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a Public Opening Position Disclosure or Dealing Disclosure made by a person holding 1% or more interest in relevant securities during a takeover situation. This type of disclosure relates to insider/significant shareholder activity during a corporate action (takeover). While it involves director/insider dealings (DIRS) and is a regulatory filing (RNS), the specific context of a takeover disclosure (Form 8.3) is not explicitly covered by the provided codes (AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, RNS, DEF 14A, RPA, SHA, POS). However, Form 8.3 is a mandatory disclosure related to insider transactions during a takeover bid. The closest fit among the provided options that captures insider trading/dealing activity is 'Director's Dealing' (DIRS). Although this is specifically about a takeover context, the core action is reporting a change in position/dealing by an interested party. Since 'TAR' (M&A Activity) is for merger *proposals* or *bids*, and this is a *disclosure* during one, DIRS is the most appropriate category for reporting personal security transactions by insiders/major holders, even if the context is a takeover. If DIRS is too narrow (as it implies directors), RNS (Regulatory Filings) is the general fallback. Given the specific nature of reporting interests/dealings under the Takeover Code, DIRS captures the essence of the filing better than the general RNS, unless the system strictly reserves DIRS for standard DTR 3.1.4R disclosures. Since this is a mandatory disclosure about security interests/dealings, DIRS is selected as the best fit for insider transaction reporting.
2023-05-04 English
Form 8.3 - Dechra Pharmaceuticals PLC
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals PLC' and references 'Rule 8.3 of the Takeover Code (the “Code”)' regarding 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE'. This type of disclosure relates to insider trading or significant ownership changes during a takeover scenario. This specific filing type (Form 8.3) is a regulatory filing related to takeover activity, which is not explicitly listed in the provided definitions (AGM-R, 10-K, AR, etc.). However, it is a mandatory disclosure to a regulatory body (The Panel's Market Surveillance Unit) concerning securities dealings. Given the options, the most appropriate general category for a specific, mandatory regulatory disclosure that doesn't fit the detailed financial reports (10-K, IR, ER) or specific corporate actions (DIV, SHA) is 'Regulatory Filings' (RNS), as it is a filing made to a regulatory service.
2023-05-02 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains the RNS Number, indicating it is a regulatory filing disseminated via the London Stock Exchange's RNS service. Section 2 marks 'An acquisition or disposal of voting rights' as the reason for notification. Section 7 details the resulting percentage of voting rights held (2.56%) after a change, crossing a threshold. This type of filing, reporting changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2023-05-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.